Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.

HIV medicine - 1 Jan 2003

Røge B T, Katzenstein T L, Nielsen H L, Gerstoft J

Abstract excerpt

OBJECTIVES: To determine resistance mutations emerging in HIV-1-infected patients experiencing their first protease inhibitor (PI)-failure on nelfinavir-containing highly active antiretroviral therapy (HAART), and to assess virological response to rescue regimens. METHODS: Plasma HIV-1 RNA from 24 patients failing nelfinavir-containing HAART was sequenced. Failure was defined as two consecutive measurements of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to HIV Reverse Transcriptase

Share to Nelfinavir

Share to Sequence Analysis, RNA

Share to Treatment Failure

Source

Identifiers

PMID: 12534958
DOI: 10.1046/j.1468-1293.2003.00133.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.PMID 12534958Read ↗

Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.Semantic proximity Read ↗

Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.Semantic proximity Read ↗

Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.Semantic proximity Read ↗

Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.Semantic proximity Read ↗

Drug Susceptibility and Resistance Mutations After First-Line Failure in Resource Limited SettingsSemantic proximity Read ↗

Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.Semantic proximity Read ↗

Deep Sequencing Reveals Minor Protease Resistance Mutations in Patients Failing a Protease Inhibitor RegimenSemantic proximity Read ↗

Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.Semantic proximity Read ↗

HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.Semantic proximity Read ↗

Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy.Semantic proximity Read ↗

HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment.Semantic proximity Read ↗

Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.